Tolosa-Hunt syndrome

Summary

Tolosa-Hunt syndrome (MONDO:0018983) is a disease. A subtype of ocular motility disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.1	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	Tolosa-Hunt syndrome
Mondo ID	MONDO:0018983
MeSH	D020333
Orphanet	64686
DOID	DOID:1278
ICD-11	969826782
NCIT	C85193
SNOMED CT	95794005
UMLS	C0040381
MedGen	21197
GARD	0007777
MedDRA	10051526
NORD	1774
Is cancer (heuristic)	no

Also known as: nonspecific inflammation of the cavernous sinus or superior orbital fissure · painful ophthalmoplegia · THS · Tolosa Hunt Syndrome · Tolosa Hunt syndrome · Tolosa-Hunt syndrome

Disease family

This is a subtype of ocular motility disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › ocular motility disease › Tolosa-Hunt syndrome

Related subtypes (5): ophthalmoplegia, strabismus, pathologic nystagmus, congenital fibrosis of extraocular muscles, Weber syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.